Ishita Drugs

{
  "main_header": {
    "sid": 444125,
    "name": "Ishita Drugs",
    "stock_name": "Ishita Drugs",
    "full_name": "Ishita Drugs & Industries Ltd",
    "name_url": "stocks-analysis/ishita-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "70.65",
    "chg": 1.54,
    "chgp": "2.23%",
    "dir": 1,
    "prev_price": "69.11",
    "mcapval": "21.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524400,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE806D01016",
    "curr_date": "Apr 01",
    "curr_time": "",
    "bse_nse_vol": "170 ",
    "exc_status": "Active",
    "traded_date": "Apr 01, 2026",
    "traded_date_str": "2026 04 01",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Ishita Drugs & Industries Ltd: Valuation Shifts Signal Price Attractiveness Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-price-attractiveness-amid-market-volatility-3923273",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/IshitaDrugsIndu_valuationdot_3923273.png",
        "date": "2026-03-30 08:00:53",
        "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade. Despite a recent sharp decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Ishita Drugs & Industries Ltd: Valuation Shift Signals Changing Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shift-signals-changing-price-attractiveness-3884246",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/IshitaDrugsIndu_valuationdot_3884246.png",
        "date": "2026-03-11 08:00:31",
        "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions amid mixed financial metrics and sector dynamics. Despite a robust share price rally in recent weeks, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers warrant a cautious approach from investors."
      },
      {
        "title": "Are Ishita Drugs & Industries Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ishita-drugs-industries-ltd-latest-results-good-or-bad-3826846",
        "imagepath": "",
        "date": "2026-02-07 19:19:19",
        "description": "Ishita Drugs & Industries Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported a net profit of ₹0.14 crores, which reflects a substantial decline compared to the previous quarter's ₹0.30 crores, indicating ongoing volatility in earnings. Revenue also saw a notable contraction, falling to ₹3.07 crores from ₹5.40 crores in Q1 FY26, marking a sharp decrease of 43.15% quarter-on-quarter. This decline in revenue is concerning as it highlights the company's struggle to maintain consistent sales growth, with year-on-year revenue also down by 6.12%.\n\nThe operating margin for the quarter was recorded at 6.19%, which is a slight decrease from the previous quarter's 6.48%. This suggests that while the company has managed to maintain some cost discipline, the overall profitability has been adversely affected by the significant drop in sales volume. Additionally, the..."
      },
      {
        "title": "Ishita Drugs Q2 FY26: Profit Slumps 26% as Revenue Volatility Persists",
        "link": "https://www.marketsmojo.com/news/result-analysis/ishita-drugs-q2-fy26-profit-slumps-26-as-revenue-volatility-persists-3826780",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/IshitaDrugsIndu_quaterlyResult_3826780.png",
        "date": "2026-02-07 17:46:41",
        "description": "Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹21.00 crores, reported disappointing results for Q2 FY26, with net profit declining 26.32% quarter-on-quarter to ₹0.14 crores from ₹0.30 crores in Q1 FY26. The sharp contraction in profitability came despite the company maintaining a relatively stable operating margin profile, raising concerns about the sustainability of earnings amidst persistent revenue volatility."
      },
      {
        "title": "Why is Ishita Drugs & Industries Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ishita-drugs-industries-ltd-fallingrising-3792375",
        "imagepath": "",
        "date": "2026-01-15 00:43:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Price Movement and Market Sentiment</strong></p>\n<p>The stock opened with a gap up of 4.26%, signalling renewed buying interest early in the session. It further climbed to an intraday high of ₹75.95, marking a 9.98% surge from the previous close. This sharp rebound came after four consecutive days of decline, suggesting a short-term trend reversal. Notably, Ishita Drugs outperformed its sector by 5.98% on the day, indicating relative strength amid broader market pressures.</p>\n<p>Investor participation has also increased significantly, with delivery volumes on 13 Jan rising by 162.97% compared to the five-day average. This surge in volume points to heightened investor interest, potentially driven by the stock’s attractive valuation metrics and recent profit growth, despite its recen..."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Mixed Fundamentals and Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-downgraded-to-strong-sell-amid-mixed-fundamentals-and-technicals-3782570",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/IshitaDrugsIndu_mojoScore_3782570.png",
        "date": "2026-01-06 08:21:38",
        "description": "Ishita Drugs & Industries Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 January 2026, reflecting a deterioration in technical indicators and persistent fundamental weaknesses. Despite a modest uptick in share price and some valuation appeal, the company’s financial trends and technical signals have raised concerns among analysts, prompting a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 109,
    "sid": "444125",
    "stock_news_url": "https://www.marketsmojo.com/news/ishita-drugs-industries-444125"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Mar-2026",
      "details": "The trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 01st April 2026 till 48 hours after the declaration of the Audited Financial Results for the quarter and Financial year ended 31st March 2026.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011",
      "datetime": "27-Feb-2026",
      "details": "Disclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drgs and Industrie Limited.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011",
      "datetime": "24-Feb-2026",
      "details": "Disclosure under regulation 29(2) of SEBI(SAST)Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ishita Drugs & Industries Ltd: Valuation Shifts Signal Price Attractiveness Amid Market Volatility

2026-03-30 08:00:53

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade. Despite a recent sharp decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector.

Read full news article

Ishita Drugs & Industries Ltd: Valuation Shift Signals Changing Price Attractiveness

2026-03-11 08:00:31

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions amid mixed financial metrics and sector dynamics. Despite a robust share price rally in recent weeks, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers warrant a cautious approach from investors.

Read full news article

Are Ishita Drugs & Industries Ltd latest results good or bad?

2026-02-07 19:19:19

Ishita Drugs & Industries Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported a net profit of ₹0.14 crores, which reflects a substantial decline compared to the previous quarter's ₹0.30 crores, indicating ongoing volatility in earnings. Revenue also saw a notable contraction, falling to ₹3.07 crores from ₹5.40 crores in Q1 FY26, marking a sharp decrease of 43.15% quarter-on-quarter. This decline in revenue is concerning as it highlights the company's struggle to maintain consistent sales growth, with year-on-year revenue also down by 6.12%. The operating margin for the quarter was recorded at 6.19%, which is a slight decrease from the previous quarter's 6.48%. This suggests that while the company has managed to maintain some cost discipline, the overall profitability has been adversely affected by the significant drop in sales volume. Additionally, the...

Read full news article

Ishita Drugs Q2 FY26: Profit Slumps 26% as Revenue Volatility Persists

2026-02-07 17:46:41

Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹21.00 crores, reported disappointing results for Q2 FY26, with net profit declining 26.32% quarter-on-quarter to ₹0.14 crores from ₹0.30 crores in Q1 FY26. The sharp contraction in profitability came despite the company maintaining a relatively stable operating margin profile, raising concerns about the sustainability of earnings amidst persistent revenue volatility.

Read full news article

Why is Ishita Drugs & Industries Ltd falling/rising?

2026-01-15 00:43:51

Intraday Price Movement and Market Sentiment

The stock opened with a gap up of 4.26%, signalling renewed buying interest early in the session. It further climbed to an intraday high of ₹75.95, marking a 9.98% surge from the previous close. This sharp rebound came after four consecutive days of decline, suggesting a short-term trend reversal. Notably, Ishita Drugs outperformed its sector by 5.98% on the day, indicating relative strength amid broader market pressures.

Investor participation has also increased significantly, with delivery volumes on 13 Jan rising by 162.97% compared to the five-day average. This surge in volume points to heightened investor interest, potentially driven by the stock’s attractive valuation metrics and recent profit growth, despite its recen...

Read full news article

Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Mixed Fundamentals and Technicals

2026-01-06 08:21:38

Ishita Drugs & Industries Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 January 2026, reflecting a deterioration in technical indicators and persistent fundamental weaknesses. Despite a modest uptick in share price and some valuation appeal, the company’s financial trends and technical signals have raised concerns among analysts, prompting a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News